
- MHE August 2023
- Volume 33
- Issue 8
A Wave of New Treatments, a Tsunami of Ultrahigh Prices
Charging more than $2 million for a single treatment was once unthinkable, but no more.
Charging more than $2 million for a single treatment was once unthinkable, but no more. Today’s gene therapies and other innovative medicines for rare diseases come with price tags that stagger the mind, and despite continuing public controversy over drug pricing, they’re not necessarily unfair.
Still, that leaves the question of how a health plan today can absorb even a single claim without looking like the misshapen boa constrictor in “The Little Prince” who famously — and visibly — had swallowed an elephant.
Related:
Below are just a few of the recent FDA-approved therapies with staggering price tags.
Articles in this issue
about 2 years ago
Between the Lines: Bempedoic Acidabout 2 years ago
Healthcare Split on Noncompete Agreementsabout 2 years ago
Why DIY? Hospitals Are Outsourcing Clinical, Nonclinical Servicesabout 2 years ago
Response Letters, Alzheimer’s Disease Drugs and Mounjaroabout 2 years ago
The Great Disenrollmentabout 2 years ago
When Drugs Became Ultra-Ultra Expensiveabout 2 years ago
Adding SERDs to the Adjuvant ArmamentariumNewsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.

















































